在对存档组织样本的回顾性分析中，HER3 在多种不同亚型的 NSCLC 中广泛表达。
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples.
机构信息
National University Hospital, Singapore, 119074, Singapore.
Daiichi Sankyo, Basking Ridge, NJ 07920, USA.
出版信息
Future Oncol. 2024;20(37):2961-2970. doi: 10.1080/14796694.2024.2398983. Epub 2024 Sep 25.
Abstract
This noninterventional study (NCT05769764) aimed to characterize human epidermal growth factor receptor 3 (HER3) expression in non-small cell lung cancer (NSCLC) by patient, clinical or tumor characteristics. HER3 immunohistochemistry was performed in archival tissue samples from patients with advanced or metastatic NSCLC. Samples were scored for membrane percent positivity and intensity. Membrane H-scores were calculated. Of 203 evaluable samples, HER3 expression was observed in 98.5%, including all histologies, genomic subtypes and regardless of prior systemic anticancer treatments. The median H-score was 140, and 70.4% had a HER3 intensity of 3+. HER3 is widely expressed in NSCLC, indicating that HER3-directed therapy may be broadly applicable across diverse subtypes of NSCLC.
摘要
这项非干预性研究（NCT05769764）旨在通过患者、临床或肿瘤特征来描述非小细胞肺癌（NSCLC）中人类表皮生长因子受体 3（HER3）的表达。对晚期或转移性 NSCLC 患者的存档组织样本进行了 HER3 免疫组织化学检测。对膜阳性百分比和强度进行了评分。计算了膜 H 评分。在 203 个可评估样本中，98.5%观察到 HER3 表达，包括所有组织学、基因组亚型，且无论先前是否接受过系统抗癌治疗。中位 H 评分为 140，70.4%的样本 HER3 强度为 3+。HER3 在 NSCLC 中广泛表达，表明 HER3 靶向治疗可能广泛适用于 NSCLC 的多种亚型。
相似文献
1
HER3 is widely expressed across diverse subtypes of NSCLC in a retrospective analysis of archived tissue samples.在对存档组织样本的回顾性分析中，HER3 在多种不同亚型的 NSCLC 中广泛表达。
Future Oncol. 2024;20(37):2961-2970. doi: 10.1080/14796694.2024.2398983. Epub 2024 Sep 25.
2
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.U31402-A-U102研究中帕妥珠单抗德卢替康（HER3-DXd）用于EGFR突变型非小细胞肺癌的转化见解与总生存期
Ann Oncol. 2024 May;35(5):437-447. doi: 10.1016/j.annonc.2024.02.003. Epub 2024 Feb 17.
3
EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.非小细胞肺癌患者循环肿瘤细胞和肿瘤组织中 EGFR 和 HER3 的表达。
Sci Rep. 2019 May 15;9(1):7406. doi: 10.1038/s41598-019-43678-6.
4
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.阻断 EGFR/AKT 信号增强 HER3 靶向药物 patritumab deruxtecan 在 EGFR 突变型非小细胞肺癌中的抗肿瘤活性。
Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17.
5
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic -mutated NSCLC.HERTHENA-Lung01 研究：曲妥珠单抗 deruxtecan（HER3-DXd）治疗既往治疗的转移性 - 突变型 NSCLC 的 II 期研究。
Future Oncol. 2023 Jun;19(19):1319-1329. doi: 10.2217/fon-2022-1250. Epub 2023 May 22.
6
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.HER3基因扩增与晚期非小细胞肺癌患者对吉非替尼的敏感性
Br J Cancer. 2005 Dec 12;93(12):1334-40. doi: 10.1038/sj.bjc.6602865.
7
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].非小细胞肺癌中PD-1与PD-L1表达及表皮生长因子受体突变的相关性研究
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):623-631. doi: 10.3779/j.issn.1009-3419.2021.102.31. Epub 2021 Aug 30.
8
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.肺腺癌亚型的分类与肿瘤细胞程序性死亡配体 1（PD-L1）表达的关联。
Pathol Oncol Res. 2021 Apr 8;27:597499. doi: 10.3389/pore.2021.597499. eCollection 2021.
9
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.PD-L1 表达及其与非小细胞肺癌患者临床病理和基因组的相关性：印度视角。
Pathol Res Pract. 2021 Dec;228:153497. doi: 10.1016/j.prp.2021.153497. Epub 2021 May 24.
10
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.一项评估抗 HER3 抗体 patritumab（U3-1287）联合厄洛替尼治疗日本非小细胞肺癌患者的 I 期研究。
Lung Cancer. 2015 Jun;88(3):275-81. doi: 10.1016/j.lungcan.2015.03.010. Epub 2015 Mar 19.
引用本文的文献
1
The Guardian Research Network: A Real-World Data Source for Pharmacoepidemiologic Research and Regulatory Applications.《卫报》研究网络：药物流行病学研究和监管应用的真实世界数据源。
Pharmacoepidemiol Drug Saf. 2025 Sep;34(9):e70202. doi: 10.1002/pds.70202.
本文引用的文献
1
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced -mutated NSCLC after a third-generation EGFR TKI.HERTHENA-Lung02：第三代EGFR TKI治疗后，帕妥珠单抗德卢替康用于晚期EGFR突变型非小细胞肺癌的III期研究。
Future Oncol. 2024 May;20(15):969-980. doi: 10.2217/fon-2023-0602. Epub 2023 Dec 14.
2
HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.HER3：在不同类型癌症中的预后意义、治疗潜力、当前挑战和未来治疗策略。
Cells. 2023 Oct 25;12(21):2517. doi: 10.3390/cells12212517.
3
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.HERTHENA-Lung01 研究：曲妥珠单抗德鲁替康（HER3-DXd）在表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和铂类化疗治疗后的表皮生长因子受体突变型非小细胞肺癌中的 II 期研究。
J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.
4
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer.HER3在乳腺癌和肺癌脑转移中频繁过表达。
Clin Cancer Res. 2023 Aug 15;29(16):3225-3236. doi: 10.1158/1078-0432.CCR-23-0020.
5
Targeting HER3 for cancer treatment: a new horizon for an old target.针对 HER3 的癌症治疗：旧靶点的新视野。
ESMO Open. 2023 Feb;8(1):100790. doi: 10.1016/j.esmoop.2023.100790. Epub 2023 Feb 8.
6
HER-3 molecular classification, expression of PD-L1 and clinical importance in breast cancer.乳腺癌的 HER-3 分子分类、PD-L1 表达及临床意义。
Bratisl Lek Listy. 2022;123(10):719-723. doi: 10.4149/BLL_2022_115.
7
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.阻断 EGFR/AKT 信号增强 HER3 靶向药物 patritumab deruxtecan 在 EGFR 突变型非小细胞肺癌中的抗肿瘤活性。
Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17.
8
EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd.表皮生长因子受体（EGFR）抑制增强了 HER3 抗体药物偶联物 HER3-DXd 的细胞摄取和抗肿瘤活性。
Cancer Res. 2022 Jan 1;82(1):130-141. doi: 10.1158/0008-5472.CAN-21-2426. Epub 2021 Sep 21.
9
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, -Mutated Non-Small Cell Lung Cancer.Patritumab Deruxtecan（HER3-DXd）在 EGFR 抑制剂耐药、突变型非小细胞肺癌中的疗效和安全性。
Cancer Discov. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21.
10
HER3 expression and MEK activation in non-small-cell lung carcinoma.非小细胞肺癌中的HER3表达与MEK激活
Lung Cancer Manag. 2021 Apr 9;10(2):LMT48. doi: 10.2217/lmt-2020-0031.
Zotero 插件